Status:
UNKNOWN
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Conditions:
Type2 Diabetes Mellitus
Microangiopathy
Eligibility:
All Genders
50-79 years
Brief Summary
Current methods based on traditional Cardiovascular risk factors are not clinically useful for identifying Type 2 Diabetes patients at risk of developing acute Cardiovascular ischemic events (ie.myoca...
Detailed Description
Objectives 1\) To examine whether the extension and degree of microangiopathy is an independent risk factor for silent myocardial and brain ischemia. 2) To evaluate whether the degree and extension o...
Eligibility Criteria
Inclusion
- a) Age from 50-79 years; b) History of type 2diabetes of at least one year. Diabetes will be defined following the American Diabetic Association criteria: fasting glucose level of at least 126 mg/dl \[7.0 mmol/l\] in two separate analyses, a non-fasting glucose level of at least 200 mg/dl \[11.1 mmol/l\] or a self-reported history of physician-diagnosed diabetes or treatment for diabetes
Exclusion
- a) Past medical history of Cardiovascular event; b) Type 1 diabetes; c) Contraindication for PET-CT or MRI d) Other concomitant disease associated with a short life expectancy
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2018
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT02248311
Start Date
September 1 2014
End Date
October 1 2018
Last Update
January 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Valle de Hebron
Barcelona, Spain, 08035